Skip to main content
Equibles
DNA logo

DNA · Ginkgo Bioworks Holdings, Inc. · Metrics

Track DNA — free

Use DNA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DNA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$9.98 +0.12 (+1.22%)
Russell 2000 member Rebalance outlook locked
Market Cap
$663.98M
Shares
67.34M
Volume · Oct 20 2.49M Avg daily vol (3M) 2M

DNA metrics

82 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$9.86
Market cap
$663.98M

Price action

20 metrics
Price change (1W)
-16.2%
Price change (30D)
+23.6%
Price change (3M)
+25.0%
Price change (6M)
+20.1%
Price change (YTD)
+18.7%
Price change (1Y)
-27.7%
Trailing year
Price change (5Y)
—
52-week high
$14.98
52-week low
$5.48
Change from 52-week high
-34.2%
Change from 52-week low
+79.9%
Annualized volatility
99.4%
Annualized volatility (3M)
119.6%
Beta
3.1
RSI (14D)
46.3
Price vs SMA 50
+10.6%
Price vs SMA 200
+15.7%
Avg volume (3M)
2.00M
Relative volume
1.2
Average dollar volume
$20.37M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
67.34M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
4.4×
reciprocal yield 22.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
5.0×
reciprocal yield 19.9%
P / book
1.6
reciprocal yield 63.3%
FCF yield
-26.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-43.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
3.5×
reciprocal yield 28.5%
EV / revenue historical average (5Y)
9.6×
reciprocal yield 10.5%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-05

Profitability

9 metrics
Gross margin
—
Operating margin
-231.1%
Trailing 12 months
Net margin
-219.6%
Gross profit (TTM)
—
Operating profit (TTM)
−$306.06M
Net income (TTM)
−$290.80M
Trailing 12 months
Diluted EPS (TTM)
$-5.64
FCF margin
-132.0%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$3.06
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-5.68
EBITDA per diluted share (TTM)
$-4.62
Net income per diluted share (TTM)
$-5.64
Operating cash flow per diluted share (TTM)
$-3.09
Free cash flow per diluted share (TTM)
$-3.23
Capital expenditures per diluted share (TTM)
$0.14
R&D per diluted share (TTM)
$4.41
Stock compensation per diluted share (TTM)
$1.47
Book value per share
$6.60

Growth

11 metrics
Revenue growth YoY
-48.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$132.42M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+6.5%
Year over year · more shares
Revenue CAGR (3Y)
-29.1%
Revenue CAGR (5Y)
+17.3%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-69.2%
Return on assets
-29.4%
Debt / equity
0.0
Current ratio
4.6
EBITDA (TTM)
−$252.03M
Free cash flow (TTM)
−$174.80M
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$84.53M
Latest balance sheet
Cash & equivalents
$84.53M
Total assets
$990.05M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$170.24M
Capital expenditures (TTM)
$4.56M
R&D (TTM)
$215.61M
SG&A (TTM)
—
Stock compensation (TTM)
$68.81M
R&D / revenue
162.8%
Stock compensation / revenue
52.0%

Ownership (13F)

9 metrics
13F filers
186
13F filer change QoQ
+9
Institutional ownership
55.1%
Conviction holders (share of 13F filers)
1.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+17.6%
Holder tenure
12.8
Price vs estimated holder cost
-91.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
11.3%

Short interest

3 metrics
Short interest
10.9%
Latest settlement · 2.7 days to cover
Days to cover
2.7d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$73,752
Insider-sentiment score
42 / 100

Risk flags

1 metrics
Going concern
—
Key facts CIK 1830214 CUSIP 37611X209 13F (30d) 16 filings 16 filers Visit website Investor relations